Conditions: Advanced Solid Tumors
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 36
Healthy volunteers: no

Brief summary:
The purpose of the study was to characterize the safety of investigational agent AG-013736, in patients with solid tumors in this First In Human trial.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None arm 4: None arm 5: None arm 6: None

Interventions: intervention 1: AG-013736 intervention 2: AG-013736 intervention 3: AG-013736 intervention 4: AG-013736 intervention 5: AG-013736 intervention 6: AG-013736
Intervention descriptions: intervention 1: Axitinib continuous oral dosing (10 mg once a day, 10 mg twice a day, 20 mg twice a day or 30 mg twice day) in the fed state intervention 2: Axitinib continuous oral dosing (20 mg twice a day) in the fed state intervention 3: Axitinib continuous oral dosing (5 mg twice a day) in the fed state intervention 4: Axitinib continuous oral dosing (15 mg once a day) in the fed state intervention 5: Axitinib continuous oral dosing (5 mg twice a day) in the fasted state intervention 6: Axitinib continuous oral dosing (2 mg twice a day on the first day of dosing, followed by 5 mg twice a day) in the fasted state

Protocol document: